Alterity Therapeutics Limited
ASX:ATH.AX
Overview | Financials
Company Name | Alterity Therapeutics Limited |
Symbol | ATH.AX |
Currency | AUD |
Price | 0.004 |
Market Cap | 17,025,076 |
Dividend Yield | 0% |
52-week-range | 0.002 - 0.009 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Geoffrey Paul Kempler B.Sc, B.Sc. |
Website | https://alteritytherapeutics.com |
An error occurred while fetching data.
About Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD